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Clinical need for bone grafting
Bones are organs of the skeletal system, providing shape, 
mechanical support and protection to the body, and 
facilitating movement. In addition, bones contribute to 
the mineral homeostasis of the body and have recently 
been found to participate in endocrine regulation of 
energy metabolism [1]. During development, bones form 
by two distinct processes [2]: intramembraneous and 
endo chondral  ossiﬁ  cation. In intramembanous ossiﬁ  ca-
tion, cells of the condensed mesenchymal tissue diﬀ  er  en-
tiate into osteoblasts and directly form bone. In contrast, 
endochondral ossiﬁ   cation involves the formation of 
cartilaginous anlage, which then undergoes calciﬁ  cation 
and invasion by blood vessels, resulting in the formation 
of new bone by mesenchymal stem cells [3].
Adult bones are supplied by blood and constantly 
undergo remodeling, which allows adaptation to 
mechanical stresses, maintenance of bone health, and 
repair of small injuries. A recent study demonstrated very 
elegantly that the coupling between osteoclastic bone 
resorption and osteoblastic bone formation is needed to 
maintain bone health, and that both processes are 
mediated by tumor growth factor-β [4]. Similarly, co-
ordinated responses of bone tissue, bone marrow, 
periosteum and surrounding soft tissues are needed for 
bone repair, which involves elements of both endo-
chondral and intramembranous ossiﬁ  cation [5]. A tight 
control of the balance between bone formation and 
resorption determines normal turnover of bone tissue 
throughout the lifetime.
Frequently, clinical situations arise where extensive 
injury, congenital malformations or diseases cause large 
bone defects, and reconstruction with tissue grafting is 
needed. Autologous grafts contain the essential compo-
nents of bone regeneration - osteogenic cells, osteo-
inductive growth factors and bone-supporting matrix - 
but are not readily available in every situation. Other 
limitations include morbidity at the donor site (which 
often heals more slowly than the repair site) and 
diﬃ   culties in preparing anatomically shaped grafts from 
the harvested bone. Alternatives, including allogeneic 
bone transplantation, have their own limitations, such as 
tissue matching, disease transmission, batch variability, 
and an inability to survive and integrate following 
implantation [6]. Additionally, the large variability in 
bone defects, the huge complexity of bone architecture, 
and the high metabolic activity of bone, necessitating 
immediate blood supply, motivate the development of 
new treatment strategies [7].
Engineering viable human bone in vitro
Current models of bone formation in vitro are based on 
the paradigm that cellular diﬀ  erentiation and function 
can be modulated by the same factors known to play a 
role during embryonic development [8]. In order to 
engineer an environment supporting bone formation, 
combina  tions of biochemical and biophysical signals 
need to be presented to the cells in a three-dimensional 
setting in a way that allows cellular interactions with the 
surrounding cells and extracellular matrix (Figure 1, left). 
Th  e complexity of signaling - with temporal and spatial 
gradients of molecular and physical factors aﬀ  ecting 
bone morphogenesis - presents signiﬁ  cant challenges to 
engineering fully viable, functional bone.
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Treatment of extensive bone defects requires 
autologous bone grafting or implantation of bone 
substitute materials. An attractive alternative has been 
to engineer fully viable, biological bone grafts in vitro 
by culturing osteogenic cells within three-dimensional 
scaff  olds, under conditions supporting bone formation. 
Such grafts could be used for implantation, but 
also as physiologically relevant models in basic and 
translational studies of bone development, disease 
and drug discovery. A source of human cells that can 
be derived in large numbers from a small initial harvest 
and predictably diff  erentiated into bone forming cells 
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grafts. We discuss the characteristics and limitations 
of various types of human embryonic and adult stem 
cells, and their utility for bone tissue engineering.
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scaﬀ  old, which provides a structural and logistic template 
for the developing tissue, and can markedly aﬀ  ect cell 
behavior (Figure 1, middle). Several types of porous 
scaﬀ   olds have been shown to support in vitro bone 
formation by human cells, including those made of 
ceramics [9,10], native and synthetic polymers [11,12] 
and composite materials [13].
Scaﬀ   old properties important for bone formation 
include: the size, distribution and shape of the pores 
[14]; surface roughness [15]; the presence of cell 
attachment sites [16]; and the biomechanics of both the 
material [17] and the scaﬀ  old structure. In general, the 
most suitable scaﬀ   olds for bone formation are those 
with large and interconnected pores (which facilitate 
cell inﬁ  ltration and matrix deposition) and rough inner 
surfaces (which facilitate cell attachment), made of 
osteoconductive materials (such as bone protein and 
hydroxyapatite), and with mechanical properties similar 
to those of native bone (both to enable load-bearing and 
stimulate osteo  genesis). Additional features of interest 
include aniso  tropic structure, capacity for vascu-
larization, and process  a  bility into anatomically correct 
shapes. Scaﬀ   olds can also incorporate and modulate 
delivery of molecular signals controlling cellular 
functions [18].
Another key component of bone tissue engineering is 
the culture system or bioreactor. Bioreactor systems can 
be designed to control transport of nutrients and oxygen 
to cells in clinically sized constructs and provide lineage-
speciﬁ  c biological stimuli in various regions of the graft 
[19]. Additionally, the development of functional, load-
bearing characteristics of the graft would be enhanced by 
the application of biophysical stimulation in order to 
attain mechanical competence in both the cartilage and 
bone regions.
Advanced bioreactor designs maintain the physio-
logical milieu in the cell microenvironment (pH, 
temperature, oxygen and nutrient delivery) by perfusion 
and conditioning of culture medium (Figure 1, right). 
Bioreactors can also be designed to recapitulate one or 
more of the developmentally relevant biophysical signals 
in a time-controlled manner. For example, increased 
mass transport and ﬂ   uid shear by medium perfusion 
[20-22], and cyclic loading [23] have been shown to 
improve osteogenesis and enable formation of homoge-
nous bone constructs. Ideally, a bioreactor system should 
be capable of coordinating biological, physiological and 
mechanical stimuli, and applying them in a spatially and 
temporally controlled manner to provide lineage-speciﬁ  c 
stimulation within clinically sized grafts.
Th  e clinical and scientiﬁ  c utility of tissue engineering 
largely depends on our ability to predictably direct cells 
to diﬀ  erentiate into the right phenotypes in a spatially 
and temporally deﬁ  ned pattern. Th   e control of environ-
mental conditions provided through the design of 
bioreactors - in conjunction with scaﬀ  olds - can help gain 
more insight into the interplay of molecular and physical 
factors that guide the development of bone from various 
types of osteogenic cells. Understanding of the develop-
mental process may then serve as feedback to the 
optimization of engineering parameters toward better 
graft designs, and towards the use of engineered grafts as 
models of development and disease.
Sources of human osteogenic cells
Th  ere are several basic considerations when choosing a 
cell source for bone tissue engineering: the choice 
Figure 1. Schematic representation of bone formation in vitro. Left: cells are growing attached to the scaff  old surface, and sense 
microenvironmental signals. Middle: porous scaff  olds off  er support and a template for new tissue formation. Cell viability is maintained by medium 
perfusion through the scaff  old interior. Right: dynamic culture in bioreactors enables control of medium fl  ow and environmental parameters 
supporting in vitro osteogenesis.
Marot et al. Stem Cell Research & Therapy 2010, 1:10 
http://stemcellres.com/content/1/2/10
Page 2 of 10between the patient’s own (autologous) cells or the use of 
another person’s (allogeneic) cells; the availability and 
ease of tissue harvesting with minimal donor site 
morbidity; the eﬃ   ciency of cell isolation and cell yield; 
the use of primary osteogenic cells with limited potential 
for proliferation, or self-renewing stem cells; the use of 
cells that have both osteogenic and vasculogenic 
potential, to support the formation of vascularized bone; 
the homogeneity of the obtained cell population and 
controllable induction of the osteogenic phenotype; 
phenotype stability and cell safety after implantation; and 
the possibility of automation and the development of 
quality control measures for the generation of cells and 
grafts.
In most cases, cells are isolated from a tissue harvest 
and expanded in vitro prior to bone construct prepara-
tion. An expansion step increases the number of osteo-
genic cells (approximately 70 × 106 osteoblasts are needed 
to form 1 cm3 of new bone) [24], but could also be used 
for selection and enrichment of the appropriate cell 
population(s). Cells with high biosynthetic activity are 
desirable for enhanced bone formation in vitro and 
subsequent integration with the host tissue. Stable 
expres  sion of the osteogenic phenotype could aid bone 
regeneration, and is critical in order to avoid non-speciﬁ  c 
tissue development. Several clinical reports of cell-based 
tissue engineering approaches for bone regeneration are 
summarized in Table 1.
Cells from bone tissue and periosteum
Adult bone tissue and periosteum can be used as sources 
of primary osteogenic cells [25-28]. Isolation techniques 
usually involve preparation of explant cultures from the 
dissected tissues, or enzymatic release of progenitor cells 
from the endosteal and periosteal layers (Figure  2a). 
Stepwise collagenase digestion has been used for the 
preparation of osteoblast-like populations with lower 
propor  tions of adherent stromal cells [25,29]. In some 
studies, fetal bone tissue has been used as a potential 
alogeneic source due to fast cell proliferation and has 
demonstrated osteogenic potential [30].
In vitro, between 20 and 40 population doublings have 
been reported for primary bone and periostal cells 
[31,32]. Studies have indicated diﬀ  erences in proliferation 
rates of the bone cells isolated by diﬀ  erent methods and 
originating from diﬀ  erent donors, as well as age-related 
declines in cell proliferation [26,27,30]. Diﬀ  erences in the 
proliferation potentials of bone cells isolated from 
diﬀ  erent sites have been observed [29,33], similar to bone 
marrow stromal cells originating from diﬀ  erent sites [34].
In most studies, the expression of osteogenic markers 
(for example, increased alkaline phosphatase activity, 
synthesis of osteopontin, bone sialoprotein, osteocalcin 
and extracellular matix calciﬁ  cation) has been noted in 
the presence of the osteogenic supplements 1,25-dihydroxy 
vitamin D3, dexamethasone, β-glycerophosphate and 
L-ascorbic acid [35,36], but only a limited amount of 
work has directly compared the functional potentials of 
osteogenic cells isolated from diﬀ  erent sources [37]. In 
addition to osteogenesis, it has been reported that 
periosteal and endosteal populations also exhibit 
chondro  genic and adipogenic diﬀ  erentiation  potential 
[31,32].
Primary human bone and periosteal cells cultured on 
porous scaﬀ  olds formed bone-like tissue [11,38,39]. In 
separate studies, bone constructs have been engineered 
from periosteal cells and used clinically to enhance 
healing of periodontal defects (Table 1).
Taken together, these studies demonstrate that primary 
osteogenic cells can be isolated from tissues discarded 
during surgical procedures and used for in vitro studies 
[33], and suggest that harvests of small tissue volumes 
from relatively accessible sites (for example, jaw bones 
during dental implant placement) could potentially be 
used for cell isolation and preparation of autologous 
grafts up to several millimeters in diameter and length. In 
contrast, due to donor site morbidity [40-42] and limited 
proliferation of primary cells, it would be diﬃ   cult  to 
envision routine preparation of large autologous grafts 
(several centimeters in diameter and length) from 
primary bone or periosteum-derived cells (Table 1). Th  e 
applicability of such approaches will strongly depend on 
developing robust cell preparation procedures from 
source tissues that are inherently variable due to donor 
age, gender, health status, systemic conditions and 
genetic background.
Adult stem cells
Adult mesenchymal stem cells capable of diﬀ  erentiation 
into bone, cartilage, adipose, muscle, tendon, ligament 
and marrow stroma have been found in a variety of 
tissues, including bone marrow, adipose tissue, synovium, 
dental pulp, cord blood, umbilical cord and others 
[43-46]. For bone regeneration, the most studied source 
has been the bone marrow, as it was recognized early that 
its stroma contains bone marrow mesenchymal stem 
cells (BMSCs) capable of forming bone and cartilage [47]. 
Bone marrow transplantation is also being used clinically 
in combination with osteoconductive materials to 
augment bone healing [6,48].
BMSCs are commonly isolated based on their adher-
ence and growth on tissue culture plastics (Figure 2b). 
Alternatively, pure bone marrow aspirates can be used to 
immunoselect BMSCs using speciﬁ   c surface markers. 
Th  e small initial numbers of immunoselected cells are 
then expanded in culture to obtain suﬃ   cient cell mass for 
therapeutic purposes. Th   e number of stem cells (0.001 to 
0.01% of the nucleated marrow cells) [43] varies between 
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age [46]. Additionally, marrow aspiration volume (up to 
150 ml) and technique can inﬂ  uence the number of iso-
lated stem cells [48]. BMSCs can, however, be culture-
expanded to large numbers and have been reported to 
reach up to 50 population doublings in vitro [49]. Impor-
tantly, studies suggest that the osteogenic potential of 
BMSCs is maintained in older individuals [46], and 
appro priate  conditions  in vitro (for example, culture on 
collagen substrate, growth factor supplementation of 
culture media) [50,51] can help maintain cell diﬀ  eren-
tiation potential.
Adipose tissue stem cells (ASCs), discovered more 
recently [44], represent another attractive source for 
bone tissue engineering due to their accessibility and 
potential for diﬀ   erentiation into osteogenic, chondro-
genic, adipogenic and endothelial lineages [52]. Lipo-
aspirate volumes can range from 100 ml to several liters 
and contain a relatively high frequency of ASCs (1 to 5% 
of isolated nucleated cells) [53]. Cell isolation protocols 
usually include density gradient centrifugation of the 
collagenase-digested tissue (lipoaspirate or minced 
adipose tissue) and culture of the adherent cell popula-
tion (Figure  2c). Similar to BMSCs, the numbers of 
Table 1. Overview of clinical studies in which tissue engineered grafts were applied for bone regeneration
 Tissue-engineered  graft   
Bone defect  preparation  Clinical evaluation  Reference
Segmental defects of long bones  Cultured bone marrow osteoprogenitors;   Callus formation and integration 2 months  [91]
(3 patients)  seeding on hydroxyapatite scaff  olds  after surgery
Large calvarial defect (1 patient)  Adipose stem cells in fi  brin glue, with   New bone formation and calvarial continuity  [92]
  autologous cancellous bone  3 months after surgery
Maxillary sinus augmentation (2 patients)  Cultured mandibular periosteal cells;   Tight interface of bone and dental implant,   [93]
  seeding and culture on polymer fl  eece   new mineralized trabecular bone and remnants
  under osteogenic conditions  of biomaterial 4 months after surgery
Maxillary sinus augmentation (27 patients)  Cultured mandibular periosteal cells;   18 patients: presence of mineralized trabecular [94]
  seeding and culture on polymer fl  eece in   bone, remnants of biomaterial and no resorption
  osteogenic conditions  3 months after surgery
    8 patients: absence of bone formation, resorption, 
    connective tissue 3 months after surgery
    1 patient: infection after surgery, removal of the graft
Posterior mandible augmentation (1 patient)  Mandibular periosteal cells on polymer   Enhanced transverse ridge dimensions, dense [95]
  fl  eece  lamellar bone 6 months after surgery
Maxillary sinus augmentation (13 patients)  Group 1: cultured mandibular periosteal   Group 1: vital woven and partially mature lamellar [96]
  cells; seeding and culture on collagen   bone 6 months after surgery, little remaining
 scaff  old in osteogenic conditions (8 patients)  biomaterial
  Group 2a: cultured maxillary osteoblasts;   Group 2a: new bone and remnants of biomaterial
  seeding and culture on natural bone mineral   at former sinus fl  oor 8 months after surgery, poorly
 scaff  old (2 patients)  vascularized connective tissue, remnants of biomaterial 
  Group 2b: natural bone mineral scaff  old   Group 2b: new bone and remnants of biomaterial
  alone (3 patients)  8 months after surgery; signifi  cantly lower bone density 
    than in groups 1 and 2a 
Maxillary sinus augmentation (20 patients)  Group 1: autologous iliac crest bone   Group 1: 29% bone resorption rate 3 months after [97]
 (10  patients)  surgery
  Group 2: cultured mandibular periosteal   Group 2: 90% graft resorption rate 3 months after
  cells; seeding and culture on polymer fl  eece   surgery, graft density corresponding to connective
  in osteogenic conditions (10 patients)  tissue in all but one augmentation
Maxillary sinus augmentation (3 patients)  Cultured mandibular periosteal cells;   New fi  brous bone and remnants of xenograft  [98]
  seeding and culture on polymer fl  eece in   bone 4 months after surgery; some maturation
  osteogenic conditions; implanted with   into lamellar bone; presence of osteoclasts 6 months
  xenograft bone  after surgery; increased bone height 18 months after 
  surgery
Maxillary sinus augmentation (7 patients)  Cultured bone marrow stem cells seeding   New bone formation and remnants of biomaterial [99]
  and 1-day culture on calcium phosphate   3 months after surgery; increased bone height
 ceramic  scaff  old  3 and 12 months after surgery
Lumbar segmental fusion (24 patients)  Group 1: autologous iliac crest cancellous   Lower donor site morbidity in group 2; higher fusion  [100]
  bone (11 patients)  rate in group 2 compared to group 1 in the period
  Group 2: cultured mandibular periosteal   3 to 9 months after surgery; comparable clinical and
  cells; seeding and culture on polymer fl  eece   radiological results (80% fusion in group 1, 90% fusion
  in osteogenic conditions (13 patients)  in group 2) 12 months after surgery
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procedure, as well as the site of tissue harvesting (for 
example, arm, thigh, abdomen, breast) [52].
Several groups have reported the formation of bone-
like constructs from BMSCs and ASCs cultured on 
porous scaﬀ  olds [54-56], and noted positive eﬀ  ects of 
dynamic bioreactor culture on cell distribution and 
matrix formation [12,20,21]. Recently, our group has 
reported engineering of fully viable, clinically sized, and 
precisely shaped temporomandibular joint grafts by 
culturing BMSCs on anatomically shaped scaﬀ  olds  in 
specially designed ‘anatomical’ bioreactors [57]. Th  is 
study illustrates the feasibility of using adult stem cells for 
engineering functional human bone grafts, and 
underlines the importance of perfusion culture to 
support physiologic cell densities, as well as formation of 
dense, homogenously distributed bone matrix.
Survival of large engineered grafts after implantation 
remains an open question due to the need for immediate 
connection to the host vasculature, which is an unsolved 
problem of all tissue engineering. Various strategies for 
pre-vascularization are currently under investigation [7]. 
For example, Scherberich and colleagues [58] obtained 
bone constructs with intrinsic vascularization potential 
by culturing isolated adipose stromal vascular fractions 
on porous scaﬀ  olds in perfusion for 5 days. Th  ese  eﬀ  orts 
could enhance the survival of implanted grafts once the 
methods become available for the connection of the graft 
to the blood supply of the host.
A few clinical studies have reported on bone constructs 
prepared from adult stem cells and implanted to enhance 
bone regeneration. Importantly, adverse side eﬀ  ects of 
the transplanted cells have not been reported, and the 
authors suggested possible positive eﬀ  ects of transplanted 
cells on bone regeneration (Table 1).
Diff  erentiation potential and phenotype stability of adult 
stem cells
Diﬀ  erentiation potentials of adult stem cells obtained from 
various sources are under investigation, as are the culture 
conditions required to achieve the functional properties of 
terminally diﬀ  erentiated cells. Another focus is determining 
correlations between the pheno  types of cultured cells and 
their potential for functional diﬀ   erentiation. Stem cells 
isolated from various tissues are frequently evaluated for the 
expression of surface antigens by ﬂ  ow cytometry [43,45], 
and share common patterns between various BMSC 
preparations, and a highly conserved proﬁ  le between ASC 
preparations [52]. In spite of the relative uniformity of 
marker expression, the cell potential to deposit bone matrix 
can vary quite signiﬁ  cantly between diﬀ  erent donors and 
cell  popu la tions  [21,59].
Figure 2: Examples of human osteogenic cells growing in vitro. (A) Primary explant culture of bone cells. (B) Bone marrow mesenchymal stem 
cells. (C) Adipose stem cells. (D) Human embryonic stem cells (line H13) growing on mouse embryonic fi  broblasts. Original magnifi  cation: 100×.
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potential of cells are provided by micromass and pellet 
cultures. Pellets are prepared by centrifugation of several 
hundred thousand cells, and incubated in diﬀ  erentiation 
media for speciﬁ  c diﬀ  erentiation paths - in most cases 
osteogenic, chondrogenic and adipogenic. Micromass 
cultures are prepared by plating droplets of high cell 
density suspensions on tissue culture plates, which are 
also incubated in speciﬁ  c cell diﬀ  erentiation media. In 
both systems, high cell density helps mimic cell inter-
actions and cell condensation events present during 
native development of cartilage and bone.
Osteogenesis and chondrogenesis can be measured 
quantitatively using molecular, biochemical and histolo-
gical assays [12,21]. Bone formation capacity can also be 
evaluated in vivo - for example, in ectopic bone formation 
models [60]. In a recent study, correlations between bone 
marker gene expression and functional osteogenesis 
assays have been made to construct a mathematical 
model for predicting the bone forming capacity of the 
synovial and periosteal stem cells [60]. In future, such 
models could possibly be implemented in culture 
protocols to help develop robust procedures for 
manufacturing bone grafts.
Several reports of long-term BMSC and ASC cultures 
(≥4 months, ≥30 doublings) have indicated changes in 
cell cycle kinetics and the possibility of abnormal 
karyotype development, leading to malignant cell trans-
for  mation [61,62]. Th  ese studies identiﬁ  ed some limita-
tions of ex vivo manipulation, which should be taken into 
consideration and explored further to ensure the 
biosafety of adult stem cells before their clinical 
application.
Embryonic stem cells and induced pluripotent stem cells
Pluripotent human embryonic stem cells (ESCs) can 
form any tissue of the body and have exhibited an 
unsurpassed (possibly unlimited) potential for prolifera-
tion in vitro [63]. ESCs were ﬁ  rst successfully isolated and 
cultured in 1998 by Th  omson and colleagues [64], and 
have enormous value as a potential source of cells for 
regenerative medicine, as well as a model of early human 
development. In bone tissue engineering, ESCs could be 
used as a single source for the derivation of multiple 
lineages present in adult bone, including osteogenic cells, 
vascular cells, osteoclasts, nerve cells and others.
Compared to adult stem cells, ESCs require complex 
culture conditions: they are commonly derived from 
blastocyst-stage embryos and cultured on mitotically 
inactivated murine feeder cells in media supplemented 
with basic ﬁ  broblast growth factor and other factors [63]. 
ESCs grow in colonies, and are passaged as small 
aggregates by mechanical or enzymatic dissociation from 
the feeder cells. In recent years, progress has been made, 
and completely deﬁ  ned feeder-free conditions have been 
reported [65]. In an alternative approach, human feeder 
cells (for example, skin ﬁ  broblasts) have been used for 
ESC culture [66].
Similar to adult stem cells, pluripotent ESCs are 
charac  terized by the expression of speciﬁ  c  surface 
antigens, including stage-speciﬁ   c embryonic antigen-4 
(SSEA-4), tumor rejection antigens TRA-1-60 and 
TRA-1-81, and the absence of SSEA-1 [67]. Other 
markers associated with undiﬀ  erentiated ESCs are high 
alkaline phosphatase and telomerase activities, and 
expres  sion of transcription factors Oct4, Sox2 and 
Nanog, which are crucial for the maintenance of pluri-
potency [68]. A standard test for conﬁ  rming human ESC 
diﬀ  erentiation  potential  in vivo is the formation of 
teratomas after cell injection in immunodeﬁ  cient mice. 
Pluripotency can also be evaluated in vitro by inducing 
diﬀ   erentiation in embryoid bodies (aggregates of cells 
cultured in suspension) and observing formation of 
tissues from all three germ layers [67].
Spontaneous development of abnormal karyotypes and 
other genetic alterations have been observed during 
prolonged cultivation of ESCs [69,70]. Th  erefore,  frequent 
monitoring of the karyotype is recommended, and 
further studies are needed to ensure stability and safety 
of the ESC-derived progenitor populations before their 
potential use in regenerative medicine.
Recently, the prospect of using ESCs for autologous 
therapies has gained attention with reports of induced 
pluripotent stem cells derived from adult diﬀ  erentiated 
cells [71]. Induced pluripotent stem cells share many 
characteristics with ESCs, including morphology, 
prolifera  tion, surface antigens, gene expression, epi-
genetic status and pluripotency. Development of safer 
alternatives for cell reprogramming (for example, 
excluding genetic manipulation) could potentially 
provide a cell source for autologous therapy [72]. 
Currently, however, these cells present a unique 
opportunity to study the development and progression of 
genetic diseases in vitro.
Osteogenesis of embryonic human stem cells
Th  e pluripotent nature of ESCs presents a challenge to 
the development of eﬃ   cient protocols for directing cells 
into speciﬁ  c lineages. Th   e embryoid body step has been 
an integral part of many diﬀ  erentiation  protocols, 
including osteogenic diﬀ   erentiation. Cells capable of 
osteo  genesis have been found in mixed populations of 
progenitor cells present in embryoid bodies after 4 to 
5 days of culture [73,74], and populations arising from 
co-cultures with primary bone and periodontal ligament 
cells [75,76]. A direct diﬀ  erentiation protocol excluding 
the embroid body step has also been tested, and seemed 
to enhance ESC osteogenesis in vitro [77].
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stem cells (MSCs) from ESCs has been attempted, and 
these MSC-like progenitors have been subsequently 
directed into the osteogenic lineage (mostly in monolayer 
culture). In one study, MSC-like progenitors have been 
obtained by mechanical isolation of spontaneously diﬀ  er-
entiated cells from ESC cultures, followed by longer 
culture in conﬂ  uent monolayers [78]. In another study, 
co-culture with stromal cells was used to induce diﬀ  eren-
tiation, followed by immunoselection of a MSC-like 
population [79]. More recently, exposure of ESCs to 
serum and growth factor supplemented media [80,81] 
has been used to induce diﬀ  erentiation, and MSC-like 
progenitors have been expanded in a subsequent mono-
layer culture. Whereas these studies elucidate some of 
the factors involved in osteogenesis of ESCs, further 
work is needed to gain a better understanding of the 
developmental processes involved in speciﬁ  cation  to 
bone-forming cells, as well as to evaluate the stability and 
functionality of the obtained populations [82].
Genetically engineered osteogenic cells
In vivo implantation of stem cells genetically engineered 
to carry osteogenic genes has been shown to induce rapid 
bone formation, indicating the possibility of enhancing 
regenerative processes by combining cell and gene therapy 
strategies. It has been hypothesized that genetically 
modiﬁ  ed cells exert both autocrine and paracrine eﬀ  ects, 
recruiting host cells to the site of implantation and 
resulting in enhanced osteogenesis [83]. Importantly, 
recruitment of host cells could allow for a reduced 
number of exogenous cells that need to be implanted. In 
many studies, adult stem cells have been engineered to 
express genes of the bone morphogenetic protein family 
(for example, BMP2, BMP4, and BMP7). Other genes of 
interest include those encoding transcription factors 
essential for osteoblast diﬀ  erentiation (for example, core 
bind  ing factor α1 (Cbfa1), and Osterix), factors enhanc-
ing angiogenesis (for example, vascular endothelial 
growth factor), and bone formation antagonists (for 
example, noggin) for an additional level of control over 
bone formation, and combinations of several factors [83]. 
Th  e challenges lay in eﬃ   ciently  delivering  therapeutic 
genes into the cells without adenoviral and retroviral 
vectors - for example, by nucleofection (a form of electro-
permeabilization) - in order to increase safety and allow 
for the subsequent development of clinical applications.
Future prospects, clinical translation and 
regulation
In addition to scientiﬁ   c challenges, several manu  fac-
turing, safety and regulatory issues need to be addressed 
before cell-based therapies can become routine clinical 
practice for the treatment of bone defects. Recently, the 
conditions allowing clinical scale production of cells for 
therapeutic purposes have been evaluated, including the 
possibility of automated culture [84,85]. Functional and 
structural criteria for bone grafts are not yet fully 
established, and might vary depending on the therapeutic 
purpose. In pre-clinical studies, load-bearing large 
animal models should generally be used to assess graft 
functionality, as research on small animals does not give 
relevant results due to major diﬀ  erences in graft size and 
healing properties.
Cell-based products are those requiring cell isolation, 
proliferation and diﬀ  erentiation, as well as application of 
supporting scaﬀ  olding materials. Under European Union 
regulations, cell-based products need to be manufactured 
in good manufacturing practice facilities under classic 
pharmaceutical standards [86,87]. Th   e regulation of cell-
based products falls under the categories of ‘human cell, 
tissue, and cellular and tissue based products’ [88,89] in 
the USA, and ‘advanced cell therapies’ in Europe as 
deﬁ  ned in [86]. In addition, the International Society for 
Stem Cell Research published Guidelines for the Clinical 
Translation of Stem Cells [90], which highlight the 
scientiﬁ  c, clinical, regulatory, ethical, and social issues to 
be addressed for cell-based products and services. Th  ese 
documents address the safety and use of therapeutic 
cells, and regulate the necessary evaluations and permis-
sions for the sourcing of material, especially for cells of 
allogeneic origin (patient information,  genetic and 
infection screening, written informed consent for donors).
As a general principle, stem cell-based approaches 
should be clinically competitive or superior to existing 
therapies. Th   e risks of using cell-based products should 
be carefully evaluated with respect to the beneﬁ  ts  of 
enhanced functional outcome, application of one single 
procedure, reduction of cost, and improved quality of 
life. Clinical trials should be based on a clear rationale 
and justiﬁ   cation of the procedure (with supporting 
preclinical data and comparisons to existing treatments), 
and should include characterization of the product, 
description of administration (including drugs and 
surgery) and plans for clinical follow-up and adverse 
events reporting.
Conclusions
Tissue-engineered bone constructs have the potential to 
alleviate the demand arising from the shortage of suitable 
autograft and allograft materials for augmenting bone 
healing. Th  ey also can serve as controllable in vitro 
models of high biological ﬁ   delity for studies of bone 
development, disease or regeneration. Each of the 
sources of osteogenic human cells - primary cells, MSCs, 
ESCs and induced pluripotent stem cells - has distinct 
advantages when used for bone tissue engineering, and 
the quest for an ‘ideal’ cell source is still in progress.
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biological potential of any cell type. To this end, advanced 
scaﬀ   olds (with molecular, structural and mechanical 
properties designed to mimic bone) and bioreactors 
(with environmental control and biophysical signaling for 
enhanced osteogenesis) are being developed to engineer 
bone grafts and to test the osteogenic capacity of stem 
cells. Because bone is a vascularized tissue that is actively 
remodeled through coordinated sequences of bone 
growth and resorbtion, the requirements are much more 
complex than ‘just’ the formation of mineralized bone 
matrix. Th   e need for a vascular compartment, as well as 
for coordinated activity of osteoblasts and osteoclasts, 
pose major challenges to directed diﬀ  erentiation of stem 
cells. Ongoing research is advancing from the ability to 
engineer centimeter-size bone tissue constructs contain-
ing viable cells and mineralized matrix to engineering 
more complex tissue constructs that more closely 
resemble native bone. It remains to be seen how much 
can be done (and needs to be done) in vitro to obtain 
bone grafts for implantation, and to study disease and 
screen cells and therapeutic agents.
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